FRIDAY, April 9, 2021 (HealthDay News) — For people with HIV receiving tenofovir-based antiretroviral therapy (ART), replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TAF) is associated with adverse metabolic changes, including weight increase and development of obesity, according to a study published online March 16 in the Annals of Internal Medicine. Bernard Surial, M.D.,...